<p><span><span><span><span><span><span><span><span><strong><span><span><span>Doha Declaration:</span></span></span></strong></span></span><span><span><span><span><span><span> World Trade Organization adopted the TRIPS Agreement in 2001 in Doha. The Doha Declaration acknowledges the role of patents in the development of new medicines, but affirms that "the TRIPS Agreement does not and should not prevent Members from taking measures to protect public health". It supports the "principles WHO has publicly advocated and advanced over the years, namely the re-affirmation of the right of WTO Members to make full use of the safeguard provisions of the TRIPS Agreement in order to protect public health and enhance access to medicines for poor countries" (WHO, <a href="https://www.who.int/medicines/areas/policy/doha_declaration/en/">https://www.who.int/medicines/areas/policy/doha_declaration/en/</a>)<br />
TRIPS: Agreement on Trade Related Aspects of Intellectual Property Rights, Including Trade in Counterfeit Goods (<a href="https://www.wto.org/english/docs_e/legal_e/27-trips_03_e.htm">https://www.wto.org/english/docs_e/legal_e/27-trips_03_e.htm</a>)<br />
TRIPS flexibilities (paragraph 6 of the Preamble of the TRIPS Agreement):<br />
“[...] the special needs of the least-developed country Members in respect of maximum flexibility in the domestic implementation of laws and regulations in order to enable them to create a sound and viable technological base.”</span></span></span></span></span></span></span></span></span></span></span></span></p>
